Eli Lilly

FDA Accepts Supplement Application for Verzenio (Abemaciclib)

The FDA has accepted a supplemental application for Verzenio (abemaciclib) from Eli Lilly.

Eli Lilly's Muvalaplin Trial Targets Cardiovascular Risk in High Lipoprotein(a) Patients

Eli Lilly is conducting a trial to assess muvalaplin's efficacy in reducing cardiovascular events in patients with elevated lipoprotein(a).

Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance

Lilly's Q1 2026 revenue surged 56% to $19.8 billion, driven by strong volume growth despite lower prices for Mounjaro and Zepbound.

Lilly to acquire Ajax Therapeutics for myelofibrosis and polycythemia vera

Lilly is acquiring Ajax Therapeutics to enhance its portfolio in treating myelofibrosis and polycythemia vera, leveraging Ajax's lead program, AJ1-11095, a first-in-class Type II JAK2 inhibitor.

Lilly to acquire Kelonia Therapeutics for in vivo CAR-T cell therapy advancement

Lilly is acquiring Kelonia Therapeutics to enhance its portfolio in in vivo CAR-T cell therapies, particularly targeting relapsed/refractory multiple myeloma.

Eli Lilly's Baricitinib Evaluated for Safety in Pediatric sJIA Patients

Eli Lilly is conducting a study to assess the safety and efficacy of baricitinib in children with systemic juvenile idiopathic arthritis.

Eli Lilly's LY3457263 Trial in Type 2 Diabetes Shows Potential Against Semaglutide and Tirzepatide

Eli Lilly is conducting a trial to evaluate LY3457263 against placebo in type 2 diabetes patients on semaglutide or tirzepatide.

Eli Lilly's Eloralintide Shows Promise for Osteoarthritis Knee Pain in Obese Patients

Eli Lilly is conducting two independent studies to evaluate the efficacy and safety of Eloralintide (LY3841136) in adults with knee osteoarthritis and obesity.

FDA Approves Supplemental Application for Retevmo (Selpercatinib)

The FDA has approved a supplemental application for Retevmo (selpercatinib) submitted by Eli Lilly.

Eli Lilly's LY4178256 Tolerance Study in Healthy Participants Initiated

Eli Lilly is conducting a study to evaluate the tolerance and side effects of LY4178256 in healthy participants over approximately 7 months.

Lilly to acquire AtaiBeckley to enhance treatment-resistant depression therapies

Eli Lilly is acquiring AtaiBeckley to advance therapies targeting treatment-resistant depression.

FDA Accepts Supplemental Application for Verzenio (Abemaciclib)

The FDA has accepted a supplemental application for Verzenio, CDK4/6 inhibitor developed by Eli Lilly.

Lilly presents new Alzheimer's diagnostic and therapeutic data at AAIC 2026

Lilly will present new data on P-tau217 blood tests and insights from Kisunla trials at AAIC 2026.

FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly

The FDA has accepted a supplemental application for OLUMIANT (Baricitinib) from Eli Lilly.

FDA Approves Supplemental Application for Strattera by Lilly

The FDA has approved a supplemental application for Strattera (atomoxetine hydrochloride) submitted by Lilly.

Eli Lilly initiates Phase 1 trial of oral IDH inhibitor LY3410738 in hematologic malignancies

Eli Lilly is conducting Phase 1 trial of LY3410738, targeting patients with IDH1 or IDH2 mutations in advanced hematologic malignancies.

FDA Accepts Supplemental Application for Emgality (Galcanezumab)

The FDA has accepted a supplemental application for Emgality, CGRP inhibitor developed by Eli Lilly.

Eli Lilly's Mazdutide Shows Promise in Alcohol Use Disorder Study

Eli Lilly is conducting a proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder.

Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines

The CHMP has issued a positive opinion for Lilly's Jaypirca (pirtobrutinib) for adults with CLL.

Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program

The Medicare GLP-1 Bridge program will provide access to Lilly's obesity treatments, Foundayo and Zepbound, for eligible Medicare Part D patients starting July 1.

Eli Lilly's Eloralintide Trial Targets Insulin Sensitivity in Obesity

Eli Lilly is conducting a 35-week trial to evaluate eloralintide's effects on insulin sensitivity and metabolic health in overweight or obese participants.

Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments

Eli Lilly has completed its acquisition of Centessa Pharmaceuticals, focusing on orexin receptor 2 agonists.

FDA Accepts Supplement for Lebrikizumab by Eli Lilly

The FDA has accepted the supplemental biologics application for Lebrikizumab (BLA761306) from Eli Lilly.

Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway

A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.

FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly

The FDA has accepted a supplemental application for Emgality, CGRP inhibitor developed by Eli Lilly.

Eli Lilly's Remternetug Study in Healthy Chinese Participants Initiated

Eli Lilly is conducting a safety and tolerability study of remternetug in healthy Chinese participants, lasting up to 25 weeks.

Eli Lilly's Orforglipron Study in Adolescents with Obesity Underway

Eli Lilly is conducting a study to evaluate the efficacy and safety of orforglipron in adolescents with obesity or related comorbidities.

Eli Lilly's Tirzepatide Study Targets Adolescents with Obesity and Comorbidities

Eli Lilly is conducting a study to evaluate tirzepatide's effects on weight and cardiovascular risk in adolescents with obesity.

Lilly to present positive Phase 3 results for pirtobrutinib in CLL at EHA 2026

Launch of Alzheimer's Disease Neuroimaging Initiative 4 to Validate Biomarkers

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) aims to validate biomarkers and improve clinical trial design for Alzheimer's disease.

Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer

A Phase III trial is underway to evaluate giredestrant against standard endocrine therapy in ER-positive, HER2-negative early breast cancer.

CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

CVS Caremark will cover Foundayo starting June 1 and Zepbound from October 1, allowing eligible patients to pay as low as $25 monthly.

Lilly expands infectious disease portfolio with three strategic acquisitions

Lilly has announced three acquisitions targeting viral and bacterial pathogens associated with significant health risks.

Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women

In clinical trials, Foundayo demonstrated significant weight loss in women across all stages of menopause, with losses up to 30.4 lbs.

FDA approves Lilly's EBGLYSS® for atopic dermatitis with unique dosing regimen

Lilly's EBGLYSS® (lebrikizumab-lbkz) is now approved for a maintenance dose every eight weeks, requiring only six injections per year.

Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial

VERVE-102 reduced PCSK9 levels by up to 88% and LDL-C by up to 62% in Phase 1b trial, with effects lasting up to 18 months.

Lilly's Foundayo shows superior A1C reduction and weight loss in pivotal diabetes trials

Foundayo (orforglipron) demonstrated a 57.1% greater reduction in A1C and significant weight loss compared to oral semaglutide in pivotal trials.

Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer

Phase 3 LIBRETTO-432 results indicate an 83% reduction in the risk of disease recurrence or death with Retevmo as adjuvant therapy.

Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes

Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.

Foundayo shows significant weight reduction in older adults with obesity in new analysis

Foundayo (orforglipron) demonstrated up to 13% body weight reduction in adults aged 65 and older with obesity.

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs (28.3%) over 80 weeks.

Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis

Lilly's AJ1-11095, a type II JAK2 inhibitor, shows an encouraging safety profile and promising clinical activity in myelofibrosis patients.

Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial

In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs and significant reductions in knee osteoarthritis pain.